Welcome to our dedicated page for Liveworld news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on Liveworld stock.
LiveWorld reports news on its business as a human-led, AI-powered digital marketing agency and software company serving healthcare, pharmaceutical and other regulated brands. Company updates focus on social and digital media compliance, expert-led moderation, community engagement, AI-powered insights, and software-enabled customer experience programs.
Recurring developments include financial results, investment in AI-based products, healthcare-ready search optimization services spanning GEO, AIO and SEO, and AI Brand Reputation Index research for pharmaceutical and OTC consumer healthcare brands. LiveWorld’s disclosures also describe how its offerings combine human review, regulatory expertise and AI tools for brand engagement and reputation intelligence.
LiveWorld (OTC:LVWD) launched its Advanced Practice Provider (APP) Program, centered on a new APP Research Council of practicing NPs and PAs across 30+ specialties. The initiative targets an overlooked audience that writes about 27% of prescriptions and influences over half of prescribing decisions.
The program offers direct APP feedback, media strategy optimization, and digital-first creative aligned with APP behavior, aiming to expand reach and improve campaign performance for pharmaceutical brands.
LiveWorld (OTC: LVWD) reported Q1 2026 revenue of $2.95 million, up about 15% year over year, with healthcare revenue of $2.8 million, up about 19%.
Net loss narrowed to $103,000 from $276,000. Cash and equivalents were $6.8 million, with net cash available for operations of $5.5 million.
LiveWorld (OTC: LVWD) reported 2025 results: $11.1M total revenue, down ~2% year-over-year, and $326K net income (3% margin), a ~376% increase versus 2024. Cash and cash equivalents were $7.313M, with net cash available for operations of $5.7M.
Management said LiveWorld increased AI investment, launched new AI solutions, and is cautiously optimistic 2026 revenues will exceed 2025 based on current bookings.
LiveWorld (OTC: LVWD) launched an integrated GEO, AIO & SEO search optimization service on March 3, 2026 to help healthcare and regulated brands manage visibility, accuracy, and authority as search shifts toward AI-generated answers.
The solution combines audits, prompt/keyword intelligence, and AI-optimized content with human review to reduce misrepresentation and compliance risk in AI-driven discovery.
LiveWorld (OTC: LVWD) unveiled a Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap on January 21, 2026, introducing seven AI solutions for healthcare marketing. The roadmap blends decades of human-reviewed conversation data, regulatory expertise, and platform engineering to deliver AI that prioritizes safety, governance, and empathy.
Available now: AI Brand Reputation Reports and a new AI Chatbot Moderation service; three additional AI web-management tools and a human-led intelligence product are slated for Q1 2026, and a learning/discovery solution for Q2 2026. Company cites top-10 pharma clients using its AI today.
LiveWorld (OTC: LVWD) reported Q3 2025 results on November 13, 2025: Total revenue $2.84M (healthcare revenue $2.6M) and net income $195K for the quarter. Q3 revenue declined ~9% versus Q3 2024 and nine-month revenue was $8.07M versus $8.49M a year earlier. The company ended Q3 with $7.69M cash and cash equivalents and defined net cash available for operations of $6.0M. Deferred revenue and current liabilities rose materially versus year-end 2024. Management reiterated continued investments in AI and product development while noting market uncertainty and potential impacts on future earnings.
LiveWorld (OTC:LVWD) reported Q2 2025 financial results with total revenues of $2.7 million, down 5% year-over-year. The company posted a net loss of $92,000, a 31% improvement from Q2 2024's loss of $134,000. Healthcare revenues reached $2.4 million in Q2 2025.
The company's cash position strengthened to $5.5 million, up $729,000 from June 30, 2024. LiveWorld continues to invest heavily in AI across three areas: business operations, client solutions, and next-generation AI software products. Management noted that client spending remains cautious due to current market conditions, expecting this trend to persist.
Additionally, LiveWorld's creative digital marketing campaign for Chiesi Global Rare Diseases was named a finalist in the 2025 MM+M Awards for the Organic Social Media category.
LiveWorld (OTC:LVWD) has released the first-ever AI Brand Reputation Index for over-the-counter (OTC) consumer healthcare brands. The study analyzes how artificial intelligence platforms like ChatGPT influence the reputation of the top 50 OTC brands across ten product categories.
According to the report, CeraVe ranked as the leading brand, followed by Neutrogena, Advil, Nature Made, and Pepto-Bismol. The analysis was conducted using major AI models including ChatGPT-4, Claude, and Perplexity AI, evaluating brands across four key reputation drivers: product satisfaction, brand trust, visibility & marketing strength, and accessibility & value.
Key findings revealed that AI visibility significantly drives consumer preference, with top performers combining high consumer trust and perceived effectiveness. The study also found that natural and heritage brand storylines resonate strongly with AI platforms, while brands with low AI footprint missed significant opportunities despite their market presence.
LiveWorld (OTC: LVWD) reported its Q1 2025 financial results with total revenues remaining flat at $2.6 million compared to Q1 2024. The company's healthcare segment contributed $2.3 million in revenue. The net loss from operations improved by 45% to $276,000 compared to $498,000 in Q1 2024.
The company's cash position decreased by $1.6 million to $5.0 million, primarily due to timing issues with contract renewals. Accounts receivable significantly increased from $682,000 to $2.3 million. LiveWorld launched its first dedicated AI product, the AI Pharma Brand Reputation Index, in Q1 and plans to release more AI products in beta later this year as part of its increased investment in artificial intelligence initiatives.
LiveWorld (OTC: LVWD) has unveiled its first AI Brand Reputation Index, analyzing how artificial intelligence influences perceptions of 50 leading pharmaceutical brands. The study, released on April 15, 2025, employs LiveWorld's proprietary AI framework to evaluate seven weighted reputation factors across major language models including ChatGPT, Perplexity, and Grok.
The index revealed that established brands like Dupixent and Keytruda maintain strong AI reputations due to clinical effectiveness and healthcare professional trust. Notably, Vertex Pharmaceuticals' Trikafta topped the rankings despite advertising, while newer therapies like Leqvio and Rybrevant struggle with AI visibility. The study also highlighted how safety concerns impact AI-driven reputation for products like Remicade and Xeljanz.
The assessment factors included:
- Efficacy
- Safety
- Healthcare professional trust
- Consumer sentiment
- Digital visibility
- Affordability
- Patient loyalty